GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Pralatrexate injection (FOLOTYN)

Local RX List renal extractBase record retrieved 2026-09-07See the evidence for this drug2 sources available - open source summaries, references and comparisons

FOLOTYN

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
FOLOTYN: reduced amount does not redefine the oncology cycle

The severe-renal per-administration dose retains the treatment schedule. ESRD avoidance with an exception is not an established dialysis dose.

Before applying: Use the complete cycle and toxicity monitoring; do not manufacture an ESRD regimen.

Also check: FOLOTYN: reduced amount does not redefine the oncology cycle

Rxlist source

GlobalRPh RX List - FOLOTYN

Product / population
Pralatrexate - FOLOTYN renal scope supplement; selected renal passages, not a complete prescribing monograph.
Renal measure
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. MDRD.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Renal dosing, restrictions and evidence limits

For MDRD eGFR 15-29 mL/min/1.73 m2, reduce the dose to 15 mg/m2. This is a per-administration dose modification, not permission to omit the underlying cycle schedule. Avoid use below eGFR 15, with or without dialysis. The source permits an exceptional benefit-risk decision with renal monitoring and toxicity-based adjustment, but supplies no validated ESRD dose. Baseline and weekly blood counts/mucositis assessment and renal/hepatic chemistry monitoring remain required.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/folotyn-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - FOLOTYN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Adult FOLOTYN regimen; severe-renal dosing must also satisfy the complete toxicity and supportive-care requirements.

Renal method: MDRD eGFR in mL/min/1.73 m2.
Retrieved: 2026-09-07

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - FOLOTYN

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Pralatrexate - FOLOTYN renal scope supplement; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. MDRD.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

FOLOTYN: reduced amount does not redefine the oncology cycle

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

dose table scope

FOLOTYN: reduced amount does not redefine the oncology cycle

The severe-renal per-administration dose retains the treatment schedule. ESRD avoidance with an exception is not an established dialysis dose.

How to use this: Use the complete cycle and toxicity monitoring; do not manufacture an ESRD regimen.

GlobalRPh RX List - FOLOTYN

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - FOLOTYNGlobalRPh RX List - FOLOTYN
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/folotyn-drug/

Exact product and population

Adult FOLOTYN regimen; severe-renal dosing must also satisfy the complete toxicity and supportive-care requirements.

RDM41-SCOPE-pralatrexate-folotyn · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - FOLOTYN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Adult FOLOTYN regimen; severe-renal dosing must also satisfy the complete toxicity and supportive-care requirements.

Renal method: MDRD eGFR in mL/min/1.73 m2.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The usual schedule is 30 mg/m2 IV over 3-5 minutes weekly for six weeks of a seven-week cycle. At eGFR 15-29, reduce the dose to 15 mg/m2. At eGFR <15, with or without dialysis, avoid use; exceptional benefit-risk use requires renal monitoring and toxicity-driven dose reduction. Assess CBC and mucositis at baseline and weekly; check renal/hepatic chemistry before the first and fourth doses of each cycle. These are selected renal instructions, not the complete toxicity hold/restart tables.

RDM41-rxlist-pralatrexate-folotyn-0975138050-C1 · Source locator: Dosage / Use in specific populations: renal impairment

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/folotyn-drug/
Retrieved
2026-09-07
Renal-function method
MDRD eGFR in mL/min/1.73 m2.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
7052538184eaf3ee90bfe54232966a2a1febd78418b08b43154d59727ebc79ef
Rxlist

GlobalRPh RX List - FOLOTYN

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Pralatrexate - FOLOTYN renal scope supplement; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR, mL/min/1.73 m2; retain body-surface-area indexing. MDRD.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

For MDRD eGFR 15-29 mL/min/1.73 m2, reduce the dose to 15 mg/m2. This is a per-administration dose modification, not permission to omit the underlying cycle schedule. Avoid use below eGFR 15, with or without dialysis. The source permits an exceptional benefit-risk decision with renal monitoring and toxicity-based adjustment, but supplies no validated ESRD dose. Baseline and weekly blood counts/mucositis assessment and renal/hepatic chemistry monitoring remain required.

RDM50-rxlist-pralatrexate-folotyn-0975138050-C1 · Source locator: Renal/ESRD dosage, lines 48-50; monitoring, lines 53-55.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/folotyn-drug/
Retrieved
2026-09-09
Renal-function method
eGFR, mL/min/1.73 m2; retain body-surface-area indexing. MDRD.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
1fd1c9f755395334d8ded24107d795d4907f539ccd849f35fb515536235e465d

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 2 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/folotyn-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
a30c956c85de6c2a5de7b0a51178e8931193fe809ce8ec75abd150f792b00ac9
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report